Autolus Therapeutics PLC (AUTL) — 8-K Filings

8-K Filings (24)

• Autolus Therapeutics Files 8-K with Investor Event Data — Apr 8, 2026 Risk: low
  Autolus Therapeutics plc filed an 8-K on April 8, 2026, to disclose information under Regulation FD. The filing includes an investor event presentation, which c
• 8-K Filing — Mar 27, 2026
• Autolus Therapeutics Announces Leadership Changes — Dec 2, 2025 Risk: medium
  Autolus Therapeutics plc announced on December 1, 2025, the departure of Dr. Christian Itin as Chief Medical Officer and the appointment of Dr. Laura Johnson as
• Autolus Therapeutics plc Files 8-K — Aug 12, 2025 Risk: low
  Autolus Therapeutics plc filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Autolus Therapeutics plc Files 8-K on Shareholder Matters — Jun 27, 2025 Risk: low
  Autolus Therapeutics plc filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders as of June 26, 2025. The filing details the
• 8-K Filing — Jun 2, 2025
• Autolus Therapeutics Appoints New Director — May 30, 2025 Risk: low
  Autolus Therapeutics plc announced on May 23, 2025, a change in its board of directors. Dr. Christian Höbat has been appointed as a new director. The company al
• Autolus Therapeutics Files 8-K — Apr 23, 2025 Risk: low
  Autolus Therapeutics plc filed an 8-K on April 23, 2025, reporting on financial statements and exhibits. The company, incorporated in England and Wales, is invo
• Autolus Therapeutics Reports Board Changes and Financials — Apr 3, 2025 Risk: low
  Autolus Therapeutics plc filed an 8-K on February 28, 2025, reporting changes in its board of directors and compensatory arrangements. The filing also includes
• Autolus Therapeutics plc Files 8-K — Mar 20, 2025 Risk: low
  Autolus Therapeutics plc filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Autolus Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Autolus Therapeutics plc filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Autolus Therapeutics plc Files 8-K — Sep 26, 2024 Risk: low
  Autolus Therapeutics plc filed an 8-K on September 26, 2024, reporting on events that occurred on the same date. The filing pertains to Regulation FD Disclosure
• AstraZeneca to Acquire Autolus Therapeutics for $6B — Sep 19, 2024 Risk: medium
  Autolus Therapeutics plc announced on September 13, 2024, that it has entered into a definitive agreement to be acquired by AstraZeneca for approximately $6.0 b
• Autolus Therapeutics Enters Material Definitive Agreement — Sep 13, 2024 Risk: medium
  Autolus Therapeutics plc announced on September 10, 2024, that it has entered into a material definitive agreement. The filing does not provide specific details
• Autolus Therapeutics Files 8-K on Shareholder Votes — Jun 28, 2024 Risk: low
  Autolus Therapeutics plc filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific d
• BioNTech to Acquire Autolus Therapeutics for $1.14B — Jun 5, 2024 Risk: medium
  Autolus Therapeutics plc announced on June 5, 2024, that it has entered into a definitive agreement to be acquired by BioNTech SE for approximately $1.14 billio
• Autolus Sells AUTO1/28 for $100M Upfront — Jun 3, 2024 Risk: medium
  Autolus Therapeutics plc announced on May 31, 2024, that it has entered into a definitive agreement to sell its AUTO1/28 product candidate and related assets to
• Autolus Sells AUTO1/299 to BioNTech for $100M Upfront — May 13, 2024 Risk: medium
  Autolus Therapeutics plc announced on May 13, 2024, that it has entered into a definitive agreement to sell its AUTO1/299 program to BioNTech SE for an upfront
• Autolus Therapeutics Appoints New CMO, Adds Director — Apr 1, 2024 Risk: low
  Autolus Therapeutics plc announced on March 26, 2024, the appointment of Dr. Christian Itin as Chief Medical Officer and the election of Ms. Sarah L. Kelly to i
• Autolus Therapeutics Closes $100M ADS Offering — Mar 14, 2024 Risk: medium
  On March 14, 2024, Autolus Therapeutics plc announced the closing of its previously announced underwritten public offering of American Depositary Shares (ADSs),
• Autolus Therapeutics Files 8-K for Regulation FD Disclosure — Feb 13, 2024 Risk: low
  Autolus Therapeutics plc filed an 8-K on February 13, 2024, to report an event occurring on the same date. The filing, identified by accession number 0001193125
• Autolus Therapeutics Sells Unregistered Equity, Raises Capital — Feb 8, 2024 Risk: medium
  Autolus Therapeutics plc entered into a material definitive agreement on February 6, 2024, involving an unregistered sale of equity securities. This indicates t
• Autolus Therapeutics Files Routine 8-K on Jan 26 — Jan 26, 2024
  Autolus Therapeutics plc filed an 8-K on January 26, 2024, reporting an event that occurred on January 22, 2024. This filing is a routine update under Regulatio
• Autolus Therapeutics Reports Officer/Director Changes, Comp. Arrangements — Jan 10, 2024
  Autolus Therapeutics plc filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024, related to the departure or election of director

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX